Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Absence of Association Between Serum Mutant p53 with HbA1c and Insulin in Brain Tumor Patients with Type 2 Diabetes Mellitus

Author(s): Hardiyanti Syarif, Rani Sauriasari*, Famila Takhwifa and Tiara Aninditha

Volume 19, Issue 2, 2023

Published on: 17 August, 2022

Article ID: e190522205028 Pages: 9

DOI: 10.2174/1573399818666220519140903

Price: $65

Abstract

Aims: This study aims to determine the prevalence of Type 2 Diabetes Mellitus (T2DM) in primary Brain Tumor (BT) subjects and assess the relationship between serum mutant p53 serum and HbA1c and insulin.

Background: T2DM is known to increase the risk of various types of cancer, which are thought to be caused by hyperglycemia, hyperinsulinemia, and inflammation. A cohort study that looked at more than 500,000 subjects with DM over 11 years showed an increased risk of different types of cancer, including brain tumors. However, several recent studies have shown the opposite. One of the important pathways in the pathogenesis of brain tumors is the p53 pathway, in which mutations in the TP53 gene can cause brain cell growth abnormalities.

Objective: The first stage involved taking subject data for the period January 2017-November 2020 from the medical records of the RSUPN Dr. Cipto Mangunkusumo Hospital Indonesia to assess the prevalence of T2DM in BT subjects. The second stage was an observational study with a crosssectional design that collected primary data on subjects (n=86) to assess the relationship between serum mutant p53 serum and HbA1c and insulin.

Methods: The analysis of serum mutant p53 serum and insulin was made using the ELISA method, while measurement of HbA1c was made using the boronate affinity method.

Result: The results show the prevalence of T2DM in BT subjects at Dr. Cipto Mangunkusumo Hospital Indonesia was relatively low (9%). Serum mutant p53 levels in T2DM (1.53 ng/mL ± 0.60) were significantly higher than in BT+T2DM and BT (P < 0.001). The HbA1c value was significantly lower in BT (5.15% ± 0.44) compared to BT+T2DM and T2DM (P < 0.001), while T2DM insulin levels (39.54 IU/mL ± 19.1) were significantly higher than BT+T2DM and BT (P < 0.001). There was no correlation between serum mutant p53 levels and HbA1c and insulin in the three groups.

Conclusion: The study concludes that the prevalence of BT with T2DM is relatively low (9%) and that serum levels of mutant p53 in T2DM subjects are higher than in subjects with BT, but there is no correlation between serum mutant p53 levels and HbA1c and insulin values. Further research needs to be conducted by analyzing p53 mutants from other specimens, such as brain tumor tissue.

Keywords: HbA1c, Insulin, Prevalence, Primary Brain Tumor, p53 Mutant, T2DM.

[1]
Diabetes Federation International. IDF Diabetes Atlas Ninth edition 2019. International Diabetes Federation 2019. Available from: http://www.idf.org/about-diabetes/facts-figures
[2]
Dankner R, Boffetta P, Balicer RD, et al. Time-dependent risk of cancer after a diabetes diagnosis in a cohort of 2.3 million adults. Am J Epidemiol 2016; 183(12): 1098-106.
[http://dx.doi.org/10.1093/aje/kwv290] [PMID: 27257115]
[3]
Tong JJ, Tao H, Hui OT, Jian C. Diabetes mellitus and risk of brain tumors: A meta-analysis. Exp Ther Med 2012; 4(5): 877-82.
[http://dx.doi.org/10.3892/etm.2012.698] [PMID: 23226742]
[4]
World Health Organization. Indonesia Source GLOBOCAN 2018. International Agency for Research on Cancer 2019; 256: 1-2. Available from: http://gco.iarc.fr/
[5]
de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer 2014; 110(9): 2361-8.
[http://dx.doi.org/10.1038/bjc.2014.150] [PMID: 24675382]
[6]
Wang Y, Sun Y, Tang J, et al. Does diabetes decrease the risk of glioma? A systematic review and meta-analysis of observational studies. Ann Epidemiol 2019; 30: 22-29.e3.
[http://dx.doi.org/10.1016/j.annepidem.2018.11.010] [PMID: 30545764]
[7]
Chaves J, Saif MW. IGF system in cancer: From bench to clinic. Anticancer Drugs 2011; 22(3): 206-12.
[http://dx.doi.org/10.1097/CAD.0b013e32834258a1] [PMID: 21178765]
[8]
Langen K-J, Stoffels G. Brain Tumors (A Handbook For The Newly Diagnosed). Nuklearmediziner 2007; 30(3): 204-11.
[http://dx.doi.org/10.1055/s-2007-981215]
[9]
Alexandru O, Ene L, Purcaru OS, et al. Plasma levels of glucose and insulin in patients with brain tumors. Curr Health Sci J 2014; 40(1): 27-36.
[http://dx.doi.org/10.12865/CHSJ.40.01.05] [PMID: 24791202]
[10]
Bernardo BM, Orellana RC, Weisband YL, et al. Association between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality. Br J Cancer 2016; 115(1): 108-14.
[http://dx.doi.org/10.1038/bjc.2016.157] [PMID: 27253176]
[11]
ADA Standards of Medical Care in Diabetes 2019; 2-6.
[12]
Gray N, Picone G, Sloan F, Yashkin A. The relationship between BMI and onset of diabetes mellitus and its complications. South Med J 2015; 108(1): 29-36.
[http://dx.doi.org/10.14423/SMJ.0000000000000214] [PMID: 25580754]
[13]
Seliger C, Meier CR, Becker C, et al. Diabetes, use of metformin, and the risk of meningioma. PLoS One 2017; 12(7)e0181089
[http://dx.doi.org/10.1371/journal.pone.0181089] [PMID: 28708856]
[14]
Sliwinska A, Kasznicki J, Kosmalski M, et al. Tumour protein 53 is linked with type 2 diabetes mellitus. J Med 2017; 76(11): 1532-9.
[http://dx.doi.org/10.4103/ijmr.IJMR]
[15]
Yin S, Van Meir EG. P53 pathway alterations in brain tumors. In: Meir E, Ed. CNS Cancer. Cancer Drug Discovery and Development. Totowa, New Jersey, USA: Humana Press, 2009.
[http://dx.doi.org/10.1007/978-1-60327-553-8_14]
[16]
Zwezdaryk K, Sullivan D, Saifudeen Z. The p53/adipose-tissue/cancer nexus. Front Endocrinol (Lausanne) 2018; 9: 457.
[http://dx.doi.org/10.3389/fendo.2018.00457] [PMID: 30158901]
[17]
Neuro-Oncology Study Group. Book of Teaching Neuro-Oncology. Jakarta: Indonesian Sociey of Neurologist (PERDOSSI) 2019.
[18]
Levine A. Targeting therapies for the p53 protein in cancer treatments. Annu Rev Cancer Biol 2019; 3(1): 21-34.
[http://dx.doi.org/10.1146/annurev-cancerbio-030518-055455]
[19]
Zhang Y, Dube C, Gibert M Jr, et al. The p53 pathway in glioblastoma. Cancers (Basel) 2018; 10(9): 297.
[http://dx.doi.org/10.3390/cancers10090297] [PMID: 30200436]
[20]
Seliger C, Ricci C, Meier CR, et al. Diabetes, use of antidiabetic drugs, and the risk of glioma. Neuro-oncol 2016; 18(3): 340-9.
[http://dx.doi.org/10.1093/neuonc/nov100] [PMID: 26093337]
[21]
Association American Diabetes. Updates to the Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41(9): 2045-7.
[http://dx.doi.org/10.2337/dc18-su09] [PMID: 30135199]
[22]
Feng Z, Hu W, Teresky AK, Hernando E, Cordon-Cardo C, Levine AJ. Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci USA 2007; 104(42): 16633-8.
[http://dx.doi.org/10.1073/pnas.0708043104] [PMID: 17921246]
[23]
Ogawa T, Sawada N, Iwasaki M, et al. Body mass index and height in relation to brain tumor risk in a Japanese population. Ann Epidemiol 2020; 51: 1-6.
[http://dx.doi.org/10.1016/j.annepidem.2020.06.001] [PMID: 32822852]
[24]
American Brain Tumor Association. Astrocytoma. Astrocytoma Learning opportunities Helpful resources 2020. Available from: https://www.abta.org/tumor_types/astrocytoma/
[25]
American Pharmacists Association. Drug Information Handbook: A Comprehensive Resource for all Clinicians and Healthcare Professionals. (21st ed.), Hudson, Ohio: Lexi-Comp 2012.
[26]
Yang F, Zou Y, Gong Q, Chen J, Li WD, Huang Q. From astrocytoma to glioblastoma: A clonal evolution study. FEBS Open Bio 2020; 10(5): 744-51.
[http://dx.doi.org/10.1002/2211-5463.12815] [PMID: 32069381]
[27]
Schwartzbaum J, Edlinger M, Zigmont V, et al. Associations between prediagnostic blood glucose levels, diabetes, and glioma. Sci Rep 2017; 7(1): 1436.
[http://dx.doi.org/10.1038/s41598-017-01553-2] [PMID: 28469238]
[28]
Seliger C, Luber C, Gerken M, et al. Use of metformin and survival of patients with high-grade glioma. Int J Cancer 2019; 144(2): 273-80.
[http://dx.doi.org/10.1002/ijc.31783] [PMID: 30091464]
[29]
Hashimoto H, Maruo T, Nakamura M, Ushio Y, Hirata M, Kishima H. Masked diabetes insipidus in pituitary metastasis from breast cancer after thalamic biopsy: A case report. J Med Case Reports 2022; 16(1): 12.
[http://dx.doi.org/10.1186/s13256-021-03229-y] [PMID: 35027091]
[30]
Tseng CH. Metformin is associated with a lower incidence of benign brain tumors: A retrospective cohort study in patients with type 2 diabetes mellitus. Biomolecules 2021; 11(10): 1405.
[http://dx.doi.org/10.3390/biom11101405] [PMID: 34680039]
[31]
Harder T, Plagemann A, Harder A. Birth weight and subsequent risk of childhood primary brain tumors: A meta-analysis. Am J Epidemiol 2008; 168(4): 366-73.
[http://dx.doi.org/10.1093/aje/kwn144] [PMID: 18579539]
[32]
Itahana Y, Itahana K. Emerging roles of p53 Family members in glucose metabolism. Int J Mol Sci 2018; 19(3): 776.
[http://dx.doi.org/10.3390/ijms19030776] [PMID: 29518025]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy